HDL-paraoxonase and Membrane Lipid Peroxidation: A Comparison between Healthy and Obese Subjects

Obesity

Volumn 18, Issue 6, 2010, Pages 1079-1084

  Ferretti, Gianna ^a   Bacchetti, Tiziana ^a   Masciangelo, Simona ^b   Bicchiega, Virginia ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 AZOBIS (2 AMIDINOPROPANE)DIHYDROCHLORIDE; ARYLDIALKYLPHOSPHATASE 1; CHEMICAL COMPOUND; HIGH DENSITY LIPOPROTEIN; MEMBRANE LIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ARYLDIALKYLPHOSPHATASE; LIPID; LIPID PEROXIDE;

ADULT; ARTERIOSCLEROSIS; ARTICLE; BODY MASS; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY WEIGHT; CASE CONTROL STUDY; HEALTH; METABOLISM; MIDDLE AGED; OBESITY; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ADULT; ARYLDIALKYLPHOSPHATASE; BODY MASS INDEX; CASE-CONTROL STUDIES; ERYTHROCYTE MEMBRANE; FEMALE; HEALTH; HUMANS; IDEAL BODY WEIGHT; LIPID PEROXIDATION; LIPID PEROXIDES; LIPIDS; LIPOPROTEINS, HDL; MEMBRANE LIPIDS; MIDDLE AGED; OBESITY; OXIDATION-REDUCTION;

EID: 77952952772     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.338     Document Type: Article

References (39)

1. Nieves DJ, Cnop M, Retzlaff B, et al., The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003; 52: 172-179.
2. Sasahara T, Yamashita T, Sviridov D, Fidge N, Nestel P,. Altered properties of high density lipoprotein subfractions in obese subjects. J Lipid Res 1997; 38: 600-611.
3. Ferretti G, Bacchetti T, Moroni C, et al., Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005; 90: 1728-1733.
4. Mutlu-Türkoglu U, Oztezcan S, Telci A, et al., An increase in lipoprotein oxidation and endogenous lipid peroxides in serum of obese women. Clin Exp Med 2003; 2: 171-174.
5. Kuno T, Hozumi M, Morinobu T, et al., Antioxidant vitamin levels in plasma and low density lipoprotein of obese girls. Free Radic Res 1998; 28: 81-86.
6. Myara I, Alamowitch C, Michel O, et al., Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. Obes Res 2003; 11: 112-120.
7. Mackness MI, Arrol S, Abbott C, Durrington PN,. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
8. Watson AD, Berliner JA, Hama SY, et al., Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
9. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G,. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 2957-2962.
10. Mackness B, Durrington P, McElduff P, et al., Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779.
11. Jaouad L, Milochevitch C, Khalil A,. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 2003; 37: 77-83.
12. Aviram M, Rosenblat M, Billecke S, et al., Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
13. Navab M, Anantharamaiah GM, Reddy ST, et al., Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-511.
14. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G,. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38: 163-169.
15. Ferretti G, Bacchetti T, Marotti E, Curatola G,. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metab Clin Exp 2003; 52: 146-151.
16. Rosenblat M, Vaya J, Shih D, Aviram M,. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005; 179: 69-77.
17. Mertens A, Verhamme P, Bielicki JK, et al., Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-1646.
18. Nishio E, Watanabe Y,. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236: 289-293.
19. Feingold KR, Memon RA, Moser AH, Grunfeld C,. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307-315.
20. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
21. Olusi SO,. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int J Obes Relat Metab Disord 2002; 26: 1159-1164.
22. Klimov AN, Kozhevnikova KA, Kuzmin AA, Kuznetsov AS, Belova EV,. On the ability of high density lipoproteins to remove phospholipid peroxidation products from erythrocyte membranes. Biochemistry Mosc 2001; 66: 300-304.
23. Ferretti G, Bacchetti T, Moroni C, Vignini A, Curatola G,. Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 2003; 1635: 48-54.
24. Mastorikou M, Mackness B, Liu Y, Mackness M,. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med 2008; 25: 1049-1055.
25. Blüher M,. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117: 241-250.
26. Ozenoglu A, Balci H, Ugurlu S, et al., The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs. Clinics (Sao Paulo) 2008; 63: 651-660.
27. Bajnok L, Seres I, Varga Z, et al., Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metab Clin Exp 2007; 56: 1542-1549.
28. Bajnok L, Csongradi E, Seres I, et al., Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis 2008; 197: 363-367.
29. Yudkin JS,. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007; 39: 707-709.
30. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K,. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci 2003; 73: 2807-2815.
31. Kuehl KS, Yeroushalmy S, Holloway PW,. Modulation of membrane composition of swine vascular smooth muscle cells by homologous lipoproteins in culture. Biochim Biophys Acta 1980; 600: 689-700.
32. Bowry VW, Stanley KK, Stocker R,. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89: 10316-10320.
33. Ferretti G, Bacchetti T, Nègre-Salvayre A, et al., Structural modifications of HDL and functional consequences. Atherosclerosis 2006; 184: 1-7.
34. Salmon S, Mazière C, Auclair M, et al., Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Biochim Biophys Acta 1992; 1125: 230-235.
35. Graham A, Hassall DG, Rafique S, Owen JS,. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis 1997; 135: 193-204.
36. Jakubowski H,. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275: 3957-3962.
37. Santanam N, Parthasarathy S,. Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis 2007; 191: 272-275.
38. Teiber JF, Billecke SS, La Du BN, Draganov DI,. Estrogen esters as substrates for human paraoxonases. Arch Biochem Biophys 2007; 461: 24-29.
39. Costa LG, Vitalone A, Cole TB, Furlong CE,. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69: 541-550.